NCT03878199View on ClinicalTrials.gov

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Essential ThrombocythemiaMyelofibrosisMyeloproliferative NeoplasmPolycythemia VeraSecondary Acute Myeloid Leukemia
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic SCT

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

DRUG

Ruxolitinib

Given PO

Trial Locations (3)

43210

Ohio State University Comprehensive Cancer Center, Columbus

75390

Simmons Cancer Center, Dallas

97239

OHSU, Portland

Sponsors
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER